MétaCan
Menu
Back to cohort
Record W2158839331 · doi:10.1093/jnci/djq508

Quality-of-Life Measurement in Randomized Clinical Trials in Breast Cancer: An Updated Systematic Review (2001–2009)

2011· review· en· W2158839331 on OpenAlexafffund
Julie Lemieux, Pamela J. Goodwin, Louise Bordeleau, Sophie Lauzier, Valérie Théberge

Bibliographic record

VenueJNCI Journal of the National Cancer Institute · 2011
Typereview
Languageen
FieldMedicine
TopicCancer survivorship and care
Canadian institutionsMcMaster UniversityMcGill UniversityUniversité LavalHôpital du Saint-SacrementJuravinski Cancer CentreCentre hospitalier universitaire de QuébecLunenfeld-Tanenbaum Research InstituteUniversity of Toronto
FundersCanadian Institutes of Health Research
KeywordsMedicineRandomized controlled trialBreast cancerClinical trialQuality of life (healthcare)PsychosocialMEDLINEPhysical therapyCancerSample size determinationInternal medicinePsychiatry

Abstract

fetched live from OpenAlex

BACKGROUND: Quality-of-life (QOL) measurement is often incorporated into randomized clinical trials in breast cancer. The objectives of this systematic review were to assess the incremental effect of QOL measurement in addition to traditional endpoints (such as disease-free survival or toxic effects) on clinical decision making and to describe the extent of QOL reporting in randomized clinical trials of breast cancer. METHODS: We conducted a search of MEDLINE for English-language articles published between May-June 2001 and October 2009 that reported: 1) a randomized clinical trial of breast cancer treatment (excluding prevention trials), including surgery, chemotherapy, hormone therapy, symptom control, follow-up, and psychosocial intervention; 2) the use of a patient self-report measure that examined general QOL, cancer-specific or breast cancer-specific QOL or psychosocial variables; and 3) documentation of QOL outcomes. All selected trials were evaluated by two reviewers, and data were extracted using a standardized form for each variable. Data are presented in descriptive table formats. RESULTS: A total of 190 randomized clinical trials were included in this review. The two most commonly used questionnaires were the European Organization for Research and Treatment of Cancer QOL Questionnaire and the Functional Assessment of Cancer Therapy/Functional Assessment of Chronic Illness Therapy. More than 80% of the included trials reported the name(s) of the instrument(s), trial and QOL sample sizes, the timing of QOL assessment, and the statistical method. Statistical power for QOL was reported in 19.4% of the biomedical intervention trials and in 29.9% of the nonbiomedical intervention trials. The percentage of trials in which QOL findings influenced clinical decision making increased from 15.2% in the previous review to 30.1% in this updated review for trials of biomedical interventions but decreased from 95.0% to 63.2% for trials of nonbiomedical interventions. Discordance between reviewers ranged from 1.1% for description of the statistical method (yes vs no) to 19.9% for the sample size for QOL. CONCLUSION: Reporting of QOL methodology could be improved.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.073
metaresearch head score (Gemma)0.274
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: Methods · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: Systematic review
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.927
Threshold uncertainty score0.385

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0730.274
Meta-epidemiology (narrow)0.0020.002
Meta-epidemiology (broad)0.0130.011
Bibliometrics0.0180.020
Science and technology studies0.0010.002
Scholarly communication0.0040.006
Open science0.0030.002
Research integrity0.0030.002
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.520
GPT teacher head0.543
Teacher spread0.022 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designSystematic review
DomainMethods
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations116
Published2011
Admission routes2
Has abstractyes

Explore more

Same venueJNCI Journal of the National Cancer InstituteSame topicCancer survivorship and careFrench-language works237,207